Financial Survey: Uniqure (QURE) and Strongbridge Biopharma (SBBP)

Uniqure (NASDAQ:QURE) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.


This table compares Uniqure and Strongbridge Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uniqure -677.98% -72.12% -36.31%
Strongbridge Biopharma -624.52% -1,224.30% -46.22%

Analyst Ratings

This is a breakdown of recent ratings for Uniqure and Strongbridge Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uniqure 0 1 10 0 2.91
Strongbridge Biopharma 0 0 4 0 3.00

Uniqure presently has a consensus price target of $45.75, suggesting a potential upside of 27.15%. Strongbridge Biopharma has a consensus price target of $16.75, suggesting a potential upside of 260.22%. Given Strongbridge Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Strongbridge Biopharma is more favorable than Uniqure.

Risk and Volatility

Uniqure has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares Uniqure and Strongbridge Biopharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Uniqure $13.11 million 101.93 -$79.26 million ($2.94) -12.24
Strongbridge Biopharma $7.05 million 30.81 -$113.48 million ($1.45) -3.21

Uniqure has higher revenue and earnings than Strongbridge Biopharma. Uniqure is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

59.3% of Uniqure shares are owned by institutional investors. Comparatively, 66.9% of Strongbridge Biopharma shares are owned by institutional investors. 2.0% of Uniqure shares are owned by company insiders. Comparatively, 4.2% of Strongbridge Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Strongbridge Biopharma beats Uniqure on 8 of the 14 factors compared between the two stocks.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with's FREE daily email newsletter.

Leave a Reply